Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Revance Therapeutics
(NQ:
RVNC
)
3.760
-0.170 (-4.33%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Revance Therapeutics
< Previous
1
2
3
4
5
6
7
8
9
Next >
Revance to Participate in the Wells Fargo Securities Healthcare Conference
September 02, 2021
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Announces Publication of Results on Static Glabellar Lines With Repeated Treatment of DaxibotulinumtoxinA for Injection From the SAKURA Clinical Program in Dermatologic Surgery
September 01, 2021
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Reports Second Quarter 2021 Financial Results, Provides Corporate Update
August 05, 2021
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Release Second Quarter 2021 Financial Results on Thursday, August 5, 2021
July 29, 2021
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Participate in Upcoming Virtual Healthcare Conferences
May 26, 2021
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Provides Update on DaxibotulinumtoxinA for Injection Pre-Approval Inspection
May 26, 2021
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Reports First Quarter 2021 Financial Results, Provides Corporate Update
May 10, 2021
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Release First Quarter 2021 Financial Results on Monday, May 10, 2021
May 03, 2021
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Showcase Clinical Findings at The Aesthetic Meeting 2021 that Supports DaxibotulinumtoxinA’s 24-Week Long Duration Profile Across Multiple Female Age Cohorts
April 27, 2021
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Announces First Patient Enrolled for DaxibotulinumtoxinA in Glabellar Lines and Cervical Dystonia in China by Fosun Pharma
April 27, 2021
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Present Data on DaxibotulinumtoxinA for Injection and Hyaluronic Acid Fillers at American Academy of Dermatology VMX Meeting 2021
April 23, 2021
From
Revance Therapeutics
Via
Business Wire
Revance to Participate in the 20th Annual Needham Virtual Healthcare Conference
April 06, 2021
From
Revance Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.